Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD): Competitive Landscape

Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD): Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics.

• GlobalData epidemiologists estimate that there were 1.19 million diagnosed prevalent cases of Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PKD & ADPKD) infection in 2024, which is expected to increase slightly to 1,23 million diagnosed prevalent cases by 2029.
• Currently, there is only one approved innovator therapy available on the market specifically for treating ADPKD.
• The PKD pipeline holds 43 molecules across all stages of R&D. However, none of the molecules are at the pre-registration stage for PKD.
• Over the past 10 years, 89 clinical trials have been conducted in PKD.
• During the past decade, acquisitions were North America’s most common deal type.

Scope

GlobalData’s Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.